RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stock Position Decreased by Rafferty Asset Management LLC

Rafferty Asset Management LLC cut its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPTFree Report) by 6.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,553 shares of the company’s stock after selling 6,606 shares during the period. Rafferty Asset Management LLC owned 0.27% of RAPT Therapeutics worth $2,275,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Exchange Traded Concepts LLC raised its stake in shares of RAPT Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,190 shares of the company’s stock worth $179,000 after purchasing an additional 1,824 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of RAPT Therapeutics by 347.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock valued at $99,000 after acquiring an additional 3,092 shares in the last quarter. Swiss National Bank raised its stake in shares of RAPT Therapeutics by 9.6% in the 3rd quarter. Swiss National Bank now owns 49,100 shares of the company’s stock valued at $816,000 after acquiring an additional 4,300 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of RAPT Therapeutics in the 4th quarter valued at approximately $233,000. Finally, SG Americas Securities LLC bought a new position in shares of RAPT Therapeutics in the 4th quarter valued at approximately $244,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $3.84 on Monday. RAPT Therapeutics, Inc. has a 1-year low of $3.82 and a 1-year high of $27.35. The business’s 50 day moving average is $6.44 and its 200-day moving average is $13.93.

RAPT Therapeutics (NASDAQ:RAPTGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, analysts anticipate that RAPT Therapeutics, Inc. will post -2.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on RAPT shares. SVB Leerink downgraded RAPT Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $42.00 to $10.00 in a research note on Wednesday, February 21st. Evercore ISI assumed coverage on RAPT Therapeutics in a report on Friday, February 16th. They issued an “outperform” rating on the stock. Leerink Partnrs lowered RAPT Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 21st. HC Wainwright reaffirmed a “neutral” rating on shares of RAPT Therapeutics in a report on Wednesday, April 10th. Finally, JPMorgan Chase & Co. lowered their target price on RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.67.

Read Our Latest Stock Report on RAPT

About RAPT Therapeutics

(Free Report)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Featured Stories

Institutional Ownership by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.